-
Chloroquine Research Workflows for Autophagy Studies
2026-09-02
Chloroquine is a versatile research tool for lysosomal stress, autophagy, cancer, immune signaling, and selected malaria or antiviral models. This practical guide distinguishes mechanism-focused assays from cytotoxicity workflows and provides concentration, timing, handling, and troubleshooting strategies for reproducible experiments.
-
iRhom2 Links Olfactory Receptors to Activity Adaptation
2026-09-02
Azzopardi and colleagues identify iRhom2 as a specialized component of olfactory sensory neurons and connect its expression to odorant receptor regulation and activity-dependent adaptation. The study combines knockout mouse transcriptomics, spatial and single-cell analyses, odor-environment perturbation, and a heterologous receptor-signaling model to propose an iRhom2/ADAM17 feedback pathway.
-
CAMLs in Blood: Phenotype and Clinical Utility
2026-09-01
The reference study reframes circulating cancer-associated macrophage-like cells (CAMLs) as biologically active, polyploid giant cells rather than incidental cellular debris. In a prospective, multi-institutional cohort, CAMLs were associated with disease progression and spread, while their myeloid, epithelial, endothelial, proliferative, and proangiogenic features suggested a possible role in pre-metastatic niche biology.
-
Nonselective β-Blockers and Hematopoietic Recovery
2026-09-01
The reference study shows that nonselective β-adrenergic blockade with Carvedilol can impair hematopoietic regeneration after allogeneic hematopoietic cell transplantation, whereas β1-selective inhibition had substantially less effect. By integrating mouse transplantation models with human cohort analyses, the work identifies transplant type, posttransplant chemotherapy, and graft cell dose as important modifiers of this association.
-
Temafloxacin Against Gram-Negative Bacteria: Key Findings
2026-08-31
Hardy’s overview compares the in vitro activity of temafloxacin with ciprofloxacin and ofloxacin across respiratory, enteric, sexually transmitted, and opportunistic Gram-negative pathogens. Its main contribution is a pathogen-by-pathogen interpretation of MIC data, showing strong activity against several respiratory organisms while identifying reduced potency against Pseudomonas aeruginosa.
-
Y-27632 Dihydrochloride: ROCK Inhibitor Workflows
2026-08-31
Build cleaner cytoskeletal, stem-cell, and extracellular-vesicle assays with a selective ROCK1/2 inhibitor. This guide translates TNBC vesicle-release findings into practical controls, dose-ranging workflows, and troubleshooting strategies for cancer research.
-
Tofacitinib Repairs RA Macrophage Dysfunction
2026-08-30
The reference study shows that GM-CSF reprograms rheumatoid arthritis macrophages into an inflammatory, metabolically stressed state marked by mitochondrial fragmentation. Tofacitinib reverses this phenotype more broadly than complex I or glycolysis-directed inhibitors by reducing GM-CSFRα–STAT5 signaling, restoring regulatory features, and improving mitochondrial organization in human and preclinical models.
-
P2Y11 Antagonist NF 340: Research Workflows
2026-08-29
NF 340 is a practical pharmacological probe for separating P2Y11-linked purinergic signaling from downstream motility and phosphorylation phenotypes. This guide translates breast cancer evidence into controlled workflows for migration, invasion, GPCR signaling, immunology research, and inflammation pathway modulation.
-
Amiloride (MK-870) Workflow for Ion Transport Assays
2026-08-28
Build cleaner ENaC, PC2, and uPAR experiments with Amiloride (MK-870) as a timed pharmacological perturbation rather than a standalone mechanistic proof. This workflow also shows how to use the compound as an external control when evaluating liposome uptake, antigen routing, and cellular immunity inspired by a recent nanovaccine study.
-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-08-28
Zhao and colleagues present a standardized whole-blood stimulation protocol for examining how metabolic interventions reshape human immune responses. The framework preserves the complexity of fresh blood while linking defined immune stimuli and metabolic perturbations to cytokine outputs, supporting reproducible cohort studies and cautious translational assay development.
-
AMPK–p62 Feedback Loop in Metabolic Stress
2026-08-27
A 2024 Autophagy study identifies a double-positive feedback loop between AMPK and SQSTM1/p62 that coordinates AMPK and NFE2L2/NRF2 activation during metabolic stress. The work connects lysosomal pH, calcium, ROS, autophagy, and antioxidant signaling, providing a mechanistic framework for interpreting STK11/LKB1- and KEAP1-altered non-small cell lung cancer.
-
1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine in Src Assays
2026-08-27
PP 3 is a structurally related negative control that helps distinguish Src-dependent biology from PP 2 off-target effects, vehicle artifacts, and pathway-adjacent signaling. This practical guide shows how to deploy the compound in kinase, vascular, ROS, and cell-signaling workflows without mistaking a control reagent for an inhibitor.
-
Recombinant Human IL-15: Assay Workflows
2026-08-26
Build controlled T-cell activation and Natural killer cell proliferation assays with a tag-free cytokine whose potency, purity, and endotoxin specifications support reproducible optimization. The workflow also shows how immune-cell assays can complement, but not replace, neural studies of early life adversity and oxytocin-dependent defensive behavior.
-
Palonosetron in CINV: Pharmacology and Clinical Evidence
2026-08-26
Ruhlmann and Herrstedt review how palonosetron differs from earlier 5-HT3 receptor antagonists through high receptor affinity, prolonged half-life, allosteric binding, and positive cooperativity. Their analysis emphasizes that these pharmacologic properties are clinically meaningful only when they improve protection against acute or delayed chemotherapy-induced nausea and vomiting without compromising tolerability.
-
Tofacitinib Assays: CP-690550 Workflow Guide
2026-08-25
This scenario-based guide helps researchers use Tofacitinib (CP-690550, Tasocitinib), SKU A4138, in immune-cell proliferation, viability, and inflammatory signaling assays. It connects formulation data, concentration benchmarks, solvent handling, and RA macrophage evidence to practical experimental decisions.